AMD Market Outlook to 2012

AMD is the most common cause of vision loss in the developed world for those over 50 years of age. We estimate there are over 20 million cases in the US and Europe. Dry AMD accounts for 90% of cases and has no suitable cure. Wet AMD drug sales will soon see the first blockbuster. Novartis achieved first to market success with their Visudyne drug in 1999. However work from Pfizer selling Macugen and Lucentis from Genentech have seen it sales reduced. These drugs are refered to in the press as ‘miracle drugs’ – saving sight for millions. But issues over prescribing still remain.

Key pricing issues remain critical to success for these drugs in the European and US markets. The UK’s health service have refused to take Lucentis due to its cost. With alternatives available how will Genentech overcome this problem, or will they hold firm. Is there room in the market for another player? With Visudyne receiving an extension on its patent a generic competitor may have been held off, but could the market sustain a generic version?

Dry AMD currently has no effective treatment, so market opportunities are available for a first-to-enter product in this market. With blockbuster status sure to happen for a Wet AMD drug, blockbuster status would be guaranteed for a drug tackling the more prevalent Dry AMD. Who will be likely to succeed?

Why You Must Buy This Report?

With charts, graphs, figures, tables and analysis this report delivers the very latest developments and an in depth review of the AMD market. This report is a vital addition to gaining an understanding of this growing sector of the pharmaceutical market, and will give your company 'the edge' over your competitors. You can not afford to be without this latest report from visiongain.

Five key questions this report answer's are:

1 - What is the market potential for AMD drugs over the next 5 years and beyond?

2 - What latest clinical trials/experimental research has been performed to develop Wet AMD drugs and how successful will they be?

3 - What is the global AMD market value of today and the future worth?

4 - How the AMD market will gain blockbuster status and why?

5 - What are the regulatory issues surrounding AMD drugs and pricing issues inherent with these regulations?

With an increasing aged population and unmet medical needs this market is set to grow rapidly, but by how much? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global AMD market.

Publication Date: 16/03/07

Pages: 57

PDF Format
Table of Contents

Price
Single User Licence $2598.00
Department Licence 5 Users $5998.00
Company-wide Intranet Licence $9998.00